PCT/GB2012/051783

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

Details for PCT/GB2012/051783

Application No.

PCT Application Number

PCT/GB/2012/051783

Publication No.

PCT Publication Number

WO/2013/014448

Applicants

PCT Patent Applicants

ASTRAZENECA AB
ASTRAZENECA UK LIMITED
BUTTERWORTH, Sam
FINLAY, Maurice, Raymond, Verschoyle
WARD, Richard, Andrew
KADAMBAR, Vasantha, Krishna
CHANDRASHEKAR, Reddy, C.
MURUGAN, Andiappan
REDFEARN, Heather, Marie

Agents

PCT Patent Agents

ASTRAZENECA INTELLECTUAL PROPERTY

Priority Data

PCT Patent Priority Data

US61/512,061 filed on July 27, 2011
US61/591,363 filed on January 27, 2012

PCT Pamphlet

The front page of the PCT Patent Application

PCT Pamphlet Front Page

Dates

Application Date

July 25, 2012

Publication Date

January 31, 2013

Earliest Priority Date

July 27, 2011

Deadlines

30 Month Date

30 Month National Phase Deadline.

January 27, 2014

31 Month Date

31 Month National Phase Deadline.

February 27, 2014

These dates are in the Past. Contact us to find out if National Phase entry is still possible.

Abstract

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

Info

PCT Patent application PCT/GB2012/051783 was filed on July 25, 2012 by ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BUTTERWORTH, Sam; FINLAY, Maurice, Raymond, Verschoyle; WARD, Richard, Andrew; KADAMBAR, Vasantha, Krishna; CHANDRASHEKAR, Reddy, C.; MURUGAN, Andiappan; REDFEARN, Heather, Marie. The title of this PCT Patent Application is "2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER" and the patent specification was published as WO/2013/014448 on January 31, 2013.

The earliest priority date for the patent application is July 27, 2011 and therefore the 30 month national phase deadline for PCT/GB/2012/051783 is January 27, 2014 and the 31 month national phase deadline for PCT/GB/2012/051783 is February 27, 2014

Legal

The information provided herein is not legal or other professional advice. The information herein may be provided from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein.